David L Bajor (David Bajor)

Publication Activity (10 Years)

Years Active: 2016-2022
Publications (10 Years): 8

Top Topics

Small Cell Lung Cancer

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer research

Current oncology (Toronto, Ont.)

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Diwakar Davar, Roberta Zappasodi, Hong Wang, Girish S Naik, Takami Sato, Todd Bauer, David L Bajor, Olivier Rixe, Walter Newman, Jingjing Qi, Aliya Holland, Phillip Wong, Lianna Sifferlen, Diane Piper, Cynthia A Sirard, Taha Merghoub, Jedd D Wolchok, Jason John Luke
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (18) (2022)
Amr Mohamed, Asfar S Azmi, Sylvia L Asa, Sree Harsha Tirumani, Amit Mahipal, Sakti Cjakrabarti, David L Bajor, J Eva Selfridge, Ahmed Omar Kaseb
Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination. Current oncology (Toronto, Ont.) 29 (11) (2022)
Christos Fountzilas, David L Bajor, Sarbajit Mukherjee, Joel Saltzman, Agnieszka K Witkiewicz, Orla Maguire, Hans Minderman, Ram Nambiar, Hanna R Rosenheck, Erik S Knudsen, Jason B Muhitch, Scott I Abrams, Chong Wang, Alan D Hutson, Kristopher Attwood, Karen A Hicks, Jennifer A Jurcevic, Pawel Kalinski, Renuka Iyer, Patrick M Boland
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Aman Opneja, Gino Cioffi, Asrar Alahmadi, Nelroy Jones, Tin-Yun Tang, Nirav Patil, David L Bajor, Joel N Saltzman, Amr Mohamed, Eva Selfridge, Ankit Mangla, Jill S Barnholtz-Sloan, Richard T Lee
Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014. Cancer medicine 10 (13) (2021)
Katelyn T Byrne, Courtney B Betts, Rosemarie Mick, Shamilene Sivagnanam, David L Bajor, Daniel A Laheru, E Gabriela Chiorean, Mark H O'Hara, Shannon M Liudahl, Craig Newcomb, Cécile Alanio, Ana P Ferreira, Byung S Park, Takuya Ohtani, Austin P Huffman, Sara A Väyrynen, Andressa Dias Costa, Judith C Kaiser, Andreanne M Lacroix, Colleen Redlinger, Martin Stern, Jonathan A Nowak, E John Wherry, Martin A Cheever, Brian M Wolpin, Emma E Furth, Elizabeth D Thompson, Lisa M Coussens, Robert A Anders
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (16) (2021)
Tithi Biswas, Afshin Dowlati, Charles A Kunos, John J Pink, Nancy L Oleinick, Shakun Malik, Pingfu Fu, Shufen Cao, Debora S Bruno, David L Bajor, Monaliben Patel, Stanton L Gerson, Mitchell Machtay
Adding Base Excision Repair Inhibitor TRC102 to standard Pemetrexed-Platinum-Radiation in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of a phase I trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Yiqing Zhao, Xiujing Feng, Yicheng Chen, J Eva Selfridge, Shashank Gorityala, Zhanwen Du, Janet M Wang, Yujun Hao, Gino Cioffi, Ronald A Conlon, Jill S Barnholtz-Sloan, Joel Saltzman, Smitha S Krishnamurthi, Shaveta Vinayak, Martina Veigl, Yan Xu, David L Bajor, Sanford D Markowitz, Neal J Meropol, Jennifer R Eads, Zhenghe Wang
5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers. Cancer research 80 (21) (2020)
Katelyn T Byrne, Nathan H Leisenring, David L Bajor, Robert H Vonderheide
CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. Journal of immunology (Baltimore, Md. : 1950) 197 (1) (2016)